For years, a "brain-computer interface" (脑机接口) could mean a research headband, a surgical implant, or a marketing slogan — and regulators had no shared dictionary. That gap started closing in 2025, when Chinese authorities began turning neurotech from a buzzword into a defined, insurable, approvable medical category.
Key takeaways
- In September 2025 the NMPA (国家药监局) approved YY/T 1987—2025, the first industry standard defining terminology for brain-computer interface (脑机接口) medical devices; it takes effect January 2026.
- In February 2025 the NMPA also released a companion standard on EEG dataset quality requirements for the machine-learning algorithms that decode BCI signals.
- In March 2025 the National Healthcare Security Administration (国家医保局) listed BCI as independent billable items, including invasive implant and non-invasive adaptation fees.
- In February 2024 the Ministry of Science and Technology issued the Ethical Guidelines for BCI Research (脑机接口研究伦理指引), covering subject privacy and consent.
- A June 2025 draft (征求意见稿) for general technical conditions of non-invasive BCI devices opened for public comment, signaling more standards to come.
Why terminology first
A terminology standard sounds dull, but it is the foundation everything else rests on. Without agreed definitions, two companies can claim the same "channel count" while measuring different things, and a hospital cannot code a procedure for reimbursement.
- YY/T 1987—2025 systematically defines BCI medical-device terms across basic concepts, paradigm types, signal processing and application scenarios.
- It is an industry (recommended) standard, not a mandatory law, but it gives manufacturers and reviewers a common language.
- Effective date is January 2026, aligning terminology with the separate pricing and clinical rules issued earlier.
International context
China is not alone in writing these rules. The US FDA and European regulators have also published BCI guidance documents, and standards bodies are debating how to test decoding performance and long-term implant safety. China's move therefore aligns with a global shift from vague promises toward auditable definitions, even if each jurisdiction keeps its own approval pathway.
The data-quality companion
Hardware definitions alone do not make a safe device. Because modern BCIs rely on algorithms trained on neural data, the NMPA addressed the dataset side first.
- The February 2025 document sets quality requirements and evaluation methods for EEG datasets used to train and validate BCI algorithms.
- Its stated purpose is to fix the lack of standards for pre-clinical trials, where inconsistent data has slowed credible evidence.
- Together with the terminology standard, it closes part of the gap between "it works in our lab" and "it can be reviewed for market approval."
Making it billable
A defined device also needs a payment path. The March 2025 pricing guidance from the National Healthcare Security Administration (国家医保局) did exactly that.
- Brain-computer interface (脑机接口) was set as an independent category of medical-service items.
- Specific items include an invasive BCI implantation fee, an invasive BCI removal fee, and a non-invasive BCI adaptation fee.
- This does not guarantee reimbursement everywhere, but it removes a structural blockage to clinical commercialization once products are approved.
Ethics and neuro-data privacy
Neural signals are unusually sensitive: they can hint at attention, emotion and intent. Chinese policy has treated this explicitly rather than leaving it to generic data law.
- The February 2024 Ethical Guidelines for BCI Research (脑机接口研究伦理指引), from the Ministry of Science and Technology, set out principles on health protection, respect for subjects and privacy.
- Broader protection comes from the Personal Information Protection Law and the Data Security Law, which treat biometric and neural data as sensitive information requiring strict handling.
- Legal commentary notes that specific, BCI-grade data-lifecycle rules are still maturing and that enforcement detail remains to be built out.
What is still draft
Not everything announced is in force. The policy stage matters, and several items are still moving.
- The June 2025 general technical conditions for non-invasive BCI devices is a draft for public comment (征求意见稿), not yet a released standard.
- The terminology standard is released and dated for January 2026 implementation, but companion technical thresholds will follow in stages.
- Readers should distinguish "filed draft" from "formally released" and from "in force" when tracking progress.
Honest limitations
- We rely on government and legal summaries (the Hubei IP Bureau and legal-professional sites); we did not read the full NMPA standard text, so exact clause wording is summarized.
- Standards are necessary but not sufficient: enforcement, clinical evidence and reimbursement levels still need to mature, and a terminology standard does not by itself approve any product.
- Neuro-data privacy draws on broader personal-information law, but BCI-specific data-handling enforcement is still emerging.
- This overview centers on national-level Chinese action; provincial pilots and hospital-level practices vary and are not enumerated here.
What readers can do now
- Device makers should map their product vocabulary and datasets to YY/T 1987—2025 before the January 2026 effective date.
- Researchers handling neural data should document consent and encryption aligned with the 2024 ethical guidelines and data-security law now.
- Observers can track the NMPA standards page and the June 2025 non-invasive draft's progress from 征求意见稿 to formal release.